BioCentury | May 30, 2020
Translation in Brief

Empirica’s glioblastoma CAR T therapy in mice; plus tumor microbiomes by tumor type, Senhwa and more

Brain cancer CAR T therapy  A McMaster University and University of Toronto team revealed in a Cell Stem Cell paper proof-of-concept data for Empirica Therapeutics’ lead product eCAR-133, a CAR T cell therapy targeting PROM1....
BioCentury | May 29, 2020
Distillery Therapeutics

The mitochondrial peptidase NLN identified as AML target

DISEASE CATEGORY: Cancer INDICATION: Acute myelogenous leukemia (AML) Inhibiting the mitochondrial peptidase NLN could treat AML and other leukemias. NLN protein levels were higher in the mitochondria of patient-derived primary AML cells than in the...
BioCentury | Feb 25, 2020
Distillery Therapeutics

Inhibiting stress response protein YCK2 to overcome antifungal resistance

DISEASE CATEGORY: Infectious disease INDICATION: Candida A team led by Bright Angel Therapeutics Inc. co-founder Leah Cowen, and including fellow co-founder Luke Whitesell, showed that inhibiting the fungal stress response kinase C. albicans YCK2 could...
BioCentury | Jan 10, 2020
Emerging Company Profile

Empirica: Building a new model for brain cancer

Empirica is developing antibody-based therapies for glioblastoma multiforme using a mouse model built to mimic the biology of recurrent brain cancer, rather than that of primary tumors. Its lead candidate is a CAR T cell...
BC Extra | Nov 25, 2019
Clinical News

Months after NASH failure, more woes for CymaBay's lead product on safety

CymaBay lost three quarters of its market value Monday after atypical histological findings prompted it to hold its lead program and discontinue two more trials, all developing seladelpar for liver indications. The $4.22 (76%) decline...
BC Extra | Nov 6, 2019
Company News

Allogene sets sights on iPS cell-based allogeneic therapies via Notch partnership

Allogene has staked its claim in iPS cell-based allogeneic therapies by partnering with Notch to develop T cell and NK cell therapies to treat non-Hodgkin lymphoma, leukemia and multiple myeloma. Moving beyond healthy donor cells...
BioCentury | Oct 25, 2019
Emerging Company Profile

Deep Genomics: Letting AI take the wheel

Deep Genomics announced its first candidate in September, pulling back the curtain on its holistic AI-enabled discovery platform that is designed to identify viable antisense oligonucleotide candidates faster than traditional discovery methods. CEO Brendan Frey...
BC Innovations | Aug 16, 2019
Emerging Company Profile

Grace: seeking cures in pathological roots

Grace Science is targeting the root of a recently discovered genetic disorder for not just the ultra-rare condition but also for common diseases including cancer. Grace Science LLC’s origins stem from the diagnosis of co-founder...
BC Innovations | Jul 25, 2019
Distillery Therapeutics

Phenylisoxazole-quinoline-based DNA gyrase inhibitor for drug-resistant

DISEASE CATEGORY: Infectious disease INDICATION: Staphylococcus A phenylisoxazole-quinoline-based inhibitor of DNA gyrase could treat drug-resistant Staphylococcus aureus infections. In vitro , the compound inhibited S. aureus DNA gyrase supercoiling activity with an IC 50 of 85...
BC Innovations | Apr 18, 2019
Emerging Company Profile

Phenomic AI: phenotypic screening for antibody discovery

Phenomic is developing a deep-learning platform that uses high-content imaging and neural networks to analyze phenotypic changes in disease models to discover therapeutic antibodies more rapidly than conventional methods. Current image analysis tools work well...
Items per page:
1 - 10 of 271
BioCentury | May 30, 2020
Translation in Brief

Empirica’s glioblastoma CAR T therapy in mice; plus tumor microbiomes by tumor type, Senhwa and more

Brain cancer CAR T therapy  A McMaster University and University of Toronto team revealed in a Cell Stem Cell paper proof-of-concept data for Empirica Therapeutics’ lead product eCAR-133, a CAR T cell therapy targeting PROM1....
BioCentury | May 29, 2020
Distillery Therapeutics

The mitochondrial peptidase NLN identified as AML target

DISEASE CATEGORY: Cancer INDICATION: Acute myelogenous leukemia (AML) Inhibiting the mitochondrial peptidase NLN could treat AML and other leukemias. NLN protein levels were higher in the mitochondria of patient-derived primary AML cells than in the...
BioCentury | Feb 25, 2020
Distillery Therapeutics

Inhibiting stress response protein YCK2 to overcome antifungal resistance

DISEASE CATEGORY: Infectious disease INDICATION: Candida A team led by Bright Angel Therapeutics Inc. co-founder Leah Cowen, and including fellow co-founder Luke Whitesell, showed that inhibiting the fungal stress response kinase C. albicans YCK2 could...
BioCentury | Jan 10, 2020
Emerging Company Profile

Empirica: Building a new model for brain cancer

Empirica is developing antibody-based therapies for glioblastoma multiforme using a mouse model built to mimic the biology of recurrent brain cancer, rather than that of primary tumors. Its lead candidate is a CAR T cell...
BC Extra | Nov 25, 2019
Clinical News

Months after NASH failure, more woes for CymaBay's lead product on safety

CymaBay lost three quarters of its market value Monday after atypical histological findings prompted it to hold its lead program and discontinue two more trials, all developing seladelpar for liver indications. The $4.22 (76%) decline...
BC Extra | Nov 6, 2019
Company News

Allogene sets sights on iPS cell-based allogeneic therapies via Notch partnership

Allogene has staked its claim in iPS cell-based allogeneic therapies by partnering with Notch to develop T cell and NK cell therapies to treat non-Hodgkin lymphoma, leukemia and multiple myeloma. Moving beyond healthy donor cells...
BioCentury | Oct 25, 2019
Emerging Company Profile

Deep Genomics: Letting AI take the wheel

Deep Genomics announced its first candidate in September, pulling back the curtain on its holistic AI-enabled discovery platform that is designed to identify viable antisense oligonucleotide candidates faster than traditional discovery methods. CEO Brendan Frey...
BC Innovations | Aug 16, 2019
Emerging Company Profile

Grace: seeking cures in pathological roots

Grace Science is targeting the root of a recently discovered genetic disorder for not just the ultra-rare condition but also for common diseases including cancer. Grace Science LLC’s origins stem from the diagnosis of co-founder...
BC Innovations | Jul 25, 2019
Distillery Therapeutics

Phenylisoxazole-quinoline-based DNA gyrase inhibitor for drug-resistant

DISEASE CATEGORY: Infectious disease INDICATION: Staphylococcus A phenylisoxazole-quinoline-based inhibitor of DNA gyrase could treat drug-resistant Staphylococcus aureus infections. In vitro , the compound inhibited S. aureus DNA gyrase supercoiling activity with an IC 50 of 85...
BC Innovations | Apr 18, 2019
Emerging Company Profile

Phenomic AI: phenotypic screening for antibody discovery

Phenomic is developing a deep-learning platform that uses high-content imaging and neural networks to analyze phenotypic changes in disease models to discover therapeutic antibodies more rapidly than conventional methods. Current image analysis tools work well...
Items per page:
1 - 10 of 271